WuXi AppTec Acquires ResearchPoint Global to Better Enable Clinical Development Worldwide

We are pleased to announce that WuXi has acquired ResearchPoint Global (RPG), a U..S-based contract research organization (CRO) with expertise spanning across all major therapeutic areas. RPG will become a wholly-owned...

WuXi AppTec Receives 2017 Global Integrated Drug R&D Services Competitive Strategy Innovation & Leadership...

We are honored to announce WuXi AppTec has been awarded the 2017 Frost & Sullivan Global Integrated Drug R&D Services Competitive Strategy Innovation & Leadership Award. The award is part of the...

WuXi NextCODE Completes $240 Million Series B Financing

We are pleased to announce that WuXi NextCODE has successfully completed a $240 million Series B financing. The company extended and completed the Series B round with investment from a consortium...

The U.S. FDA Completed Pre-License Inspection (PLI) of WuXi Biologics CGMP Manufacturing Facilities for...

We are pleased to announce that the U.S. Food and Drug Administration has completed the Pre-License Inspection (PLI) of WuXi Biologics cGMP manufacturing facilities for production of TMB-355 (ibalizumab) with no...

WuXi’s Pharmaceutical Development Services Division Merges with STA

We are excited to announce that WuXi subsidiary STA Pharmaceutical Co., Ltd. (STA)  has merged with our Pharmaceutical Development Services (PDS) division. The PDS division offers pre-formulation development, formulation development, as...

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

INNOVATION THAT MATTERS

Creating a New Legacy: A Look Inside Takeda’s R&D Transformation

By Rich Soll, SVP of Research Service Division at WuXi AppTec (@richsollwx) Over the last several years, the Japanese giant Takeda Pharmaceutical Company Limited (Takeda)...